← Back to headlines
RBC Capital Lifts BioCryst Pharmaceuticals Price Target Ahead of Q1 2026 Results
RBC Capital has increased its price target for BioCryst Pharmaceuticals (BCRX) as part of its preview of Q1 2026 results in the biotech sector. This adjustment reflects RBC Capital's updated outlook on the company's financial prospects.
1 May, 07:58 — 1 May, 07:58
Sources
Showing 1 of 1 sources
